-
1 month ago | 
neurologylive.com | Jiwon Oh |Isabella Ciccone
WATCH TIME: 6 minutes“This finding has several clinical and clinical trial implications, particularly for trial design in the future.
-
Oct 11, 2024 | 
medscape.com | Jiwon Oh
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. A few days after returning from the ECTRIMS Congress in Copenhagen, Dr Jiwon Oh shares how trial results may affect her day-to-day work in the clinic, particularly in relapsing multiple sclerosis (MS). One highlight that could directly affect patient care was the trial results for tolebrutinib.
-
Sep 26, 2024 | 
medscape.com | Jiwon Oh
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Jiwon Oh, MD, PhD, reporting from ECTRIMS 2024, emphasizes the significance of findings on disease-modifying treatments in MS.
-
Aug 29, 2024 | 
medscape.com | Jiwon Oh
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The 2024 ECTRIMS meeting, to be held September 18-20 in Copenhagen, Denmark, will cover a broad range of topics on disease-modifying therapy in relapsing-remitting multiple sclerosis (RRMS).
-
Aug 29, 2024 | 
medscape.com | Jiwon Oh
closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Jiwon Oh, MD, PhD, expects to gain valuable insights into disease-modifying therapy in relapsing-remitting multiple sclerosis at ECTRIMS 2024.
-
Jul 4, 2024 | 
nature.com | Jiwon Oh |Amit Bar-Or
Immunological profiling has revealed biological signatures of multiple sclerosis (MS) that could help with early, accurate diagnosis of the disease and with identifying disease subtypes that could inform treatment decisions. The findings are important steps along the path towards precision medicine for people with MS.
-
Feb 11, 2024 | 
neurologylive.com | Jiwon Oh
February 11, 2024The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital shared thoughts on the promising advancements in the multiple sclerosis field for 2024. [WATCH TIME: 5 minutes]WATCH TIME: 5 minutes“I'm really excited about the upcoming revisions to the MS diagnostic criteria. There was a large group of clinicians and scientists that met a few months ago to discuss proposed revisions.
-
Jan 1, 2024 | 
nature.com | Jiwon Oh |Luca Capezzuto |Lito Kriara |Johan van Beek |Corrado Bernasconi |Xavier Montalban | +6 more
AbstractFloodlight Open was a global, open-access, digital-only study designed to understand the drivers and barriers in deployment and use of a smartphone app in a naturalistic setting and broad study population of people with and without multiple sclerosis (MS).
-
Dec 21, 2023 | 
neurologylive.com | Jiwon Oh |Amit Bar-Or
December 21, 2023Experts conclude their discussion with pearls on the treatment of smouldering multiple sclerosis and prospective advances in medicine.
-
Dec 21, 2023 | 
neurologylive.com | Jiwon Oh |Amit Bar-Or
December 21, 2023Experts discuss holistic approaches to care for patients with multiple sclerosis (MS), including lifestyle changes and managing comorbidities. TranscriptJiwon Oh, MD, PhD: You mentioned earlier when we were talking about the various drivers of smoldering MS [multiple sclerosis], you mentioned the role of things like comorbidities in aging. And so right now it does sound like you do talk to your patients about smoldering MS.
